{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-013057","form_type":"8-K","ticker":"IMRX","cik":"0001790340","company_name":"Immuneering Corp","filed_at":"2022-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.048025+00:00","generated_at":"2026-06-24T01:31:07.227321+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Immuneering Q2 net loss $11.5M; IND for IMM-1-104 on track this quarter","bullets":["Net loss of $11.5M ($0.44 per share) vs $8.0M ($1.61) in Q2 2021.","Cash and marketable securities $128.1M as of June 30, 2022, down from $150.2M at Dec 31, 2021.","Management reiterates FY 2022 GAAP operating expense guidance of $55M-$60M.","IND filing for IMM-1-104 (pan-KRAS/NRAS) expected this quarter; first patient enrollment expected Q4 2022.","IND application for IMM-6-415 (MEK-IO program) expected in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-013057","json":"https://secwatch.observer/filing/0001558370-22-013057.json","markdown":"https://secwatch.observer/filing/0001558370-22-013057.md","text":"https://secwatch.observer/filing/0001558370-22-013057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1790340/000155837022013057/0001558370-22-013057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1790340/000155837022013057/imrx-20220810x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:31:07.227321+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}